Disufenton/acetylcysteine

Drug Profile

Disufenton/acetylcysteine

Alternative Names: Disufenton/N-acetylcysteine; HPN-07/NAC; NHPN-1010; NXY-059/NAC

Latest Information Update: 10 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Otologic Pharmaceutics
  • Class Benzenesulfonates; Nitrogen oxides; Small molecules; Sulfur amino acids
  • Mechanism of Action Free radical inhibitors; Oxygen radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Sensorineural hearing loss
  • Research Tinnitus

Most Recent Events

  • 01 Feb 2015 Otologic Pharmaceutics completes a phase I trial for Sensorineural hearing loss (In volunteers) in USA (NCT02259595)
  • 30 Oct 2014 Otologic Pharmaceutics plans a phase I trial for Sensorineural hearing loss (In volunteers) in USA (NCT02259595)
  • 01 Oct 2014 Phase-I clinical trials in Sensorineural hearing loss (In volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top